newsfilter
← Latest News
GlobeNewswire·

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the "Company")), a leading developer of next-generation antibody-based cancer therapies, today